Published in Cancer Res on February 01, 2004
Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer (2010) 5.26
Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival. Br J Cancer (2009) 1.65
Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci U S A (2005) 1.60
EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion. Am J Pathol (2005) 1.41
Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett (2009) 1.26
EphB2 and EphB4 receptors forward signaling promotes SDF-1-induced endothelial cell chemotaxis and branching remodeling. Blood (2006) 1.23
Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis. J Oncol (2010) 1.17
Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis. Adv Cancer Res (2012) 1.17
Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth. Neoplasia (2006) 1.06
Eph receptors and ephrins: therapeutic opportunities. Annu Rev Pharmacol Toxicol (2014) 1.04
Identification of alterations in DNA copy number in host stromal cells during tumor progression. Proc Natl Acad Sci U S A (2006) 0.99
Three-dimensional structure of the EphB2 receptor in complex with an antagonistic peptide reveals a novel mode of inhibition. J Biol Chem (2007) 0.98
Eph receptors and ephrins as targets for cancer therapy. J Cell Mol Med (2012) 0.98
Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging. Org Biomol Chem (2014) 0.87
[DLys(6)]-luteinizing hormone releasing hormone-curcumin conjugate inhibits pancreatic cancer cell growth in vitro and in vivo. Int J Cancer (2011) 0.83
Loss of expression of EphB1 protein in serous carcinoma of ovary associated with metastasis and poor survival. Int J Clin Exp Pathol (2013) 0.82
Overexpression of the B-type Eph and ephrin genes correlates with progression and pain in human pancreatic cancer. Oncol Lett (2012) 0.82
Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines. Oncogenesis (2012) 0.81
Inhibition of Eph receptor-ephrin ligand interaction by tea polyphenols. Pharmacol Res (2012) 0.80
EPH-EPHRIN in human gastrointestinal cancers. World J Gastrointest Oncol (2010) 0.79
NANOSCALE SELF-ASSEMBLY FOR DELIVERY OF THERAPEUTICS AND IMAGING AGENTS. Technol Innov (2011) 0.78
Novel strategy for selection of monoclonal antibodies against highly conserved antigens: phage library panning against ephrin-B2 displayed on yeast. PLoS One (2012) 0.77
Genetic alterations and epigenetic alterations of cancer-associated fibroblasts. Oncol Lett (2016) 0.75
Recombinant chimeric antibody hCAb as a novel anti-human colorectal carcinoma agent. Mol Med (2007) 0.75
The Role of Ephs and Ephrins in Memory Formation. Int J Neuropsychopharmacol (2016) 0.75
Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets. PLoS One (2016) 0.75
Paradoxes of the EphB1 receptor in malignant brain tumors. Cancer Cell Int (2017) 0.75
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature (2006) 6.56
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008) 5.54
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
Recurrent R-spondin fusions in colon cancer. Nature (2012) 5.10
The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature (2004) 5.05
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell (2007) 4.11
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol (2005) 4.02
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science (2009) 3.87
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 3.53
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res (2006) 3.34
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol (2010) 3.15
The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res (2003) 2.91
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst (2005) 2.74
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol (2012) 2.43
Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol (2009) 2.36
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res (2008) 2.33
Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer (2006) 2.27
Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther (2009) 2.16
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med (2011) 2.10
Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther (2012) 2.03
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A (2011) 2.01
IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol (2011) 1.95
The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res (2007) 1.90
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest (2009) 1.89
PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell (2010) 1.75
Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Res (2005) 1.69
Identification and immunotherapeutic targeting of antigens induced by chemotherapy. Nat Biotechnol (2006) 1.68
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. J Natl Cancer Inst (2013) 1.68
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res (2010) 1.63
Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res (2007) 1.59
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res (2011) 1.56
Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res (2009) 1.56
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res (2012) 1.55
Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem (2003) 1.54
HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res (2004) 1.49
Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling. PLoS One (2011) 1.46
p21-activated kinase 1: PAK'ed with potential. Oncotarget (2011) 1.44
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res (2009) 1.41
Hath1, down-regulated in colon adenocarcinomas, inhibits proliferation and tumorigenesis of colon cancer cells. Cancer Res (2004) 1.38
A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res (2013) 1.38
Phosphatidylserine receptor Tim-4 is essential for the maintenance of the homeostatic state of resident peritoneal macrophages. Proc Natl Acad Sci U S A (2010) 1.38
Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET. Nucl Med Biol (2010) 1.38
Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. J Clin Invest (2010) 1.36
COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res (2004) 1.35
Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies. PLoS One (2010) 1.34
Neuropilin-1 expression in cancer and development. J Pathol (2011) 1.34
Molecular basis for negative regulation of the glucagon receptor. Proc Natl Acad Sci U S A (2012) 1.33
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res (2011) 1.31
Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B. Dev Cell (2011) 1.29
In situ validation of an intestinal stem cell signature in colorectal cancer. Gut (2012) 1.26
Inhibition of epithelial ductal branching in the prostate by sonic hedgehog is indirectly mediated by stromal cells. J Biol Chem (2003) 1.25
Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing. Oncologist (2014) 1.24
Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int Immunol (2006) 1.20
Quantification of tumor tissue populations by multispectral analysis. Magn Reson Med (2004) 1.20
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood (2009) 1.19
Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res (2013) 1.18
Regulation of epithelial branching morphogenesis and cancer cell growth of the prostate by Wnt signaling. PLoS One (2008) 1.16
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res (2002) 1.15
EphB2 is a prognostic factor in colorectal cancer. Clin Cancer Res (2005) 1.11
Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood (2007) 1.11
Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis. Magn Reson Med (2010) 1.10
Liposomal packaging generates Wnt protein with in vivo biological activity. PLoS One (2008) 1.09
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood (2007) 1.09
High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing. Clin Cancer Res (2014) 1.09
MAGI-1: a widely expressed, alternatively spliced tight junction protein. Exp Cell Res (2002) 1.08
GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo. Clin Cancer Res (2012) 1.07
Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease. Mod Pathol (2010) 1.07
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Sci Transl Med (2011) 1.06
Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res (2002) 1.06
Notch3 signalling promotes tumour growth in colorectal cancer. J Pathol (2011) 1.06
Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res (2004) 1.06
Antibody-drug conjugates: an emerging modality for the treatment of cancer. Ann N Y Acad Sci (2014) 1.04
Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin Cancer Res (2008) 1.04
Plasmalemmal vesicle-associated protein (PLVAP) is expressed by tumour endothelium and is upregulated by vascular endothelial growth factor-A (VEGF). J Pathol (2005) 1.04
Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling. J Biol Chem (2002) 1.03
High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate. Br J Haematol (2007) 1.03
Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier. Clin Cancer Res (2012) 1.02
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res (2013) 1.02
Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth. Cancer Res (2003) 1.02
Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. J Pathol (2009) 1.02
Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci Transl Med (2013) 1.01